Dexpramipexole Dihydrochloride

盐酸右旋普拉克索

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameDexpramipexole Dihydrochloride
Drug Alias Namedexpramipexolum右普拉克索右旋普拉克索(+)-R-Pramipexole dihydrochloridedexpramipexole +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonistsFree radicals scavengersApoptosis inhibitors
TargetsDopamine receptorsFree radicals
Therapy Area/IndicationsEosinophilic AsthmaHypereosinophilic SyndromeRenal Insufficiency +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesUniversity Of Virginia
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdAreteia Therapeutics IncQuotient Sciences - Philadelphia Llc +[4] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgBiogen IncUniversity Of Pittsburgh +[6] 
Active IndicationsHypereosinophilic SyndromeAmyotrophic Lateral SclerosisPulmonary Eosinophilia +[5] 
Inactive IndicationsEosinophilic AsthmaRenal InsufficiencyAlzheimer Disease +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG